發(fā)布時(shí)間：2018-03-05 13:04

  本文選題：唑來(lái)膦酸　切入點(diǎn)：經(jīng)皮椎體成形術(shù)　出處：《中國(guó)藥房》2017年29期 　論文類型：期刊論文

【摘要】：目的:探討唑來(lái)膦酸注射液聯(lián)合經(jīng)皮椎體成形術(shù)對(duì)骨質(zhì)疏松性椎體壓縮骨折(OVCF)患者的臨床效果及安全性。方法。選擇2014年1月-2015年12月在我院進(jìn)行治療的OVCF患者130例,按隨機(jī)數(shù)字表法分為觀察組和對(duì)照組,各65例。對(duì)照組患者應(yīng)用經(jīng)皮椎體成形術(shù)注射骨水泥治療,觀察組患者在對(duì)照組基礎(chǔ)上加用唑來(lái)膦酸注射液5 mg,ivgtt(滴注時(shí)間≥15 min),1年1次。兩組患者術(shù)后均口服鈣劑和維生素D。觀察兩組患者治療后1周、6個(gè)月的視覺(jué)模擬量表(VAS)評(píng)分、Oswestry功能障礙指數(shù)(ODI)、日常生活能力量表(ADL)評(píng)分,檢測(cè)兩組患者治療后1年的腰椎L1~L4和股骨頸的骨密度,并記錄不良反應(yīng)發(fā)生情況。結(jié)果:治療前,兩組患者VAS評(píng)分、ODI、ADL評(píng)分以及腰椎L1~L4和股骨頸的骨密度比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療后1周、6個(gè)月,兩組患者VAS評(píng)分、ODI顯著降低,ADL評(píng)分顯著升高,且觀察組患者顯著優(yōu)于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05);治療后1年,觀察組患者腰椎L1~L4和股骨頸的骨密度均顯著增高,且觀察組顯著優(yōu)于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者發(fā)熱、頭暈、骨關(guān)節(jié)痛、肌肉軟組織疼痛、新骨折等不良反應(yīng)發(fā)生率比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:唑來(lái)膦酸聯(lián)合經(jīng)皮椎體成形術(shù)治療OVCF能明顯減輕患者疼痛,改善其功能障礙,增強(qiáng)骨密度,并具有較高的安全性。
[Abstract]:Objective: to investigate the clinical effect and safety of zoledronic acid injection combined with percutaneous vertebroplasty in patients with osteoporotic vertebral compression fracture. Methods: a total of 130 patients with OVCF treated in our hospital from January 2014 to December 2015 were selected. The patients in the control group were treated with percutaneous vertebroplasty and bone cement injection. The patients in the observation group were treated with zoledronic acid injection 5 mg / d iv gtt (drip time 鈮，

本文編號(hào)：1570356